RedHill Biopharma reported $2.69M in EBIT for its fiscal quarter ending in June of 2023.





Ebit Change Date
Cara Therapeutics USD -5.94M 3.55M Sep/2025
Clal Biotechnology ILS -5.44M 3.76M Dec/2022
Compugen USD 56.04M 63.94M Dec/2025
Cronos Group USD -7.06M 62.31M Dec/2025
RedHill Biopharma USD 2.69M 47.97M Jun/2023